Qiagen N.V. ~Nasdaq Bio~ QGEN Due Diligence
QGEN Company Overview & Description
QIAGEN N.V. is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
We have developed and market more than 500 consumable products and automated solutions. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs more than 3,800 people in over 35 locations worldwide.
QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research.
Milestones: QIAGEN - Sample & Assay Technologies
QIAGEN - Who We Are.flv - YouTube
QGEN Key Company Management
Peer M. Schatz Managing Director, Chief Executive Officer, has spearheaded the development of QIAGEN’s strategic focus on sample and assay technologies and the efforts to bring these technologies to customers in molecular diagnostics, applied testing, academia and the pharmaceutical industry. Mr. Schatz joined QIAGEN in 1993, when the company had just 30 employees and revenues of approximately $2 million. Under his direction, QIAGEN has grown to employ more than 3,700 people in over 35 locations around the world and boasts revenues of more than US$ 1 billion. He has also led QIAGEN to listings on the NASDAQ, making QIAGEN the first German company to do so, as well as the Frankfurt Stock Exchange. Mr. Schatz, a Swiss and Austrian citizen, was born in New York and grew up in the United States and Switzerland. He studied business and social sciences at the University of St. Gallen, Switzerland, where he graduated with a Masters in Finance in 1989. He later obtained a Masters of Business Administration (MBA) from the University of Chicago Graduate School in Business in 1990. Prior to 1993, Mr. Schatz held various positions at Sandoz AG and Computerland and participated in the foundation of startup companies in the computer and software trading industry in both Europe and the United States. He is a member of the German Corporate Governance Commission. He also serves as a member of the Managing Board of PMS Asset Management GmbH and holds director positions of AdvaMedDx (Unites States In-Vitro diagnostics industry organization) and ALSSA (United States Analytical & Life Science Systems Associaton).
QGEN Contact Info
Qiagen NV
Spoorstraat 50
Venlo, 5911 KJ
Netherlands
Phone: 31 77 320 8400
Fax: 31 77 320 8409
Website:
http://www1.qiagen.com
QGEN Recent Developments
SEC Filings
http://www.qiagen.com/about/investor...alreports.aspx
Competitors
QGEN Competitors | Qiagen N.V. Stock - Yahoo! Finance
Industry
QGEN Industry: Research Services | Qiagen N.V. Stock - Yahoo! Finance
Headlines
QGEN Headlines | Qiagen N.V. Stock - Yahoo! Finance
Ownership
Ownership - Qiagen N.V. - Barrons.com
QGEN Products
Product Brochure: QIAGEN Productguide 2010-11
Financial Reporting/Disclosure & Security Details
QGEN follows under these quidelines on the Nasdaq information market tier and Frankfurt tier under the symbol Frankfurt , Prime Standard: QIA
Investigate more @
QGEN QIAGEN N.V.: Summary, Stock Quote & Trades for QIAGEN N.V. - OTCMarkets.com or
PYCK Global Marketing for more due diligence.
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com,
Bloomberg - Business & Financial News, Breaking News Headlines,
Yahoo! Finance - Business Finance, Stock Market, Quotes, News, QGEN website
Qiagen N.V. ~Nasdaq Bio~
Linear Mode
